UK markets closed

Pfizer Inc (PFE.DU)

Dusseldorf - Dusseldorf Delayed price. Currency in EUR
Add to watchlist
24.02+0.11 (+0.46%)
At close: 07:30PM CEST
Full screen
Previous close23.92
Open24.00
Bid24.00 x 0
Ask24.07 x 0
Day's range23.95 - 24.09
52-week range23.59 - 37.40
Volume158
Avg. volume113
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Yahoo Finance Video

    Pfizer raises full-year outlook, stock rises on Q1 beat

    Pfizer (PFE) shares tick up in pre-market trading — continuing into the green after the market open — after the pharmaceutical giant raised its full-year profit outlook and topped first-quarter earnings estimates on the top and bottom lines. Yahoo Finance Health Reporter Anjalee Khemlani joins The Morning Brief to discuss Pfizer's outlook on its future product pipeline. For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Luke Carberry Mogan.

  • Yahoo Finance Video

    Fed rate decision, Qualcomm earnings: What to Watch

    Market Domination Overtime anchors Julie Hyman and Josh Lipton preview the top headlines for investors for tomorrow, Wednesday, May 1, 2024. Federal Reserve officials will issue their latest interest rate policy decision coming out of their FOMC meeting tomorrow afternoon, followed by a press conference by Fed Chair Jerome Powell. On the earnings front, a slew of companies are set to release quarterly reports, including names like DoorDash (DASH), Mastercard (MA), and Qualcomm (QCOM). For more expert insight and the latest market action, click here to watch this full episode of Market Domination Overtime. This post was written by Angel Smith

  • Benzinga

    Pfizer Embraces Direct-To-Consumer Model For Covid Antiviral, Says Comirnaty Revenues Continue To Perform Consistently With Expectations

    On Wednesday, Pfizer Inc. (NYSE:PFE) reported first-quarter adjusted EPS of $0.82, down 33% year over year, beating the consensus of $0.54. The company witnesses a significant decrease in Comirnaty and Paxlovid revenues globally and an unfavorable impact of foreign exchange of $107 million, or 1%. The U.S. drugmaker reported sales of $14.9 billion, down 20%, beating the consensus of $14.2 billion. Excluding contributions from Comirnaty and Paxlovid, revenues totaled $12.5 billion, an increase of